A mechanistic approach for in‐vitro anticancer activity via nucleic acid fragmentation by copper(II) complex anchored on MCM‐41
作者:Suhana Karim、Sanchari Dasgupta、Rumana Parveen、Subhendu Biswas、Debasis Das
DOI:10.1002/aoc.6571
日期:2022.4
Three new mononuclear copper Schiff base complexes, namely, ([Cu(L1)Cl].CH3CN (HmC_1), [Cu(L2)Cl].CH3CN (HmC_2) and [Cu(L3)Cl].CH3CN (HmC_3) derived from ONO donor tridentate ligands HL1, HL2 and HL3, respectively, have been synthesized to check their efficacy as target-specific next-generation anticancer therapeutics. All the HmCs have been characterized by using various physicochemical techniques
三种新型单核铜席夫碱配合物,即([Cu(L1)Cl].CH 3 CN ( HmC_1 )、[Cu(L2)Cl].CH 3 CN ( HmC_2 )和[Cu(L3)Cl].CH 3 CN ( HmC_3 ) 分别来自 ONO 供体三齿配体HL1、HL2和HL3,已被合成以检查其作为靶向特异性下一代抗癌治疗剂的功效。 , 单晶 X 射线分析, 傅里叶变换红外 [FT-IR] 光谱和元素分析). 在合成的席夫碱配合物中, HmC_3在培养的人乳腺癌细胞系 (MDA-MB-231) 和人肺癌细胞系 (A549) 上进行的杀灭癌细胞最有效。最后,为了提高细胞渗透性,通过将HmC_3固定在合适的基质MCM-41@APTES(MCM-41 = Mobil Composition of Matter No. 41 和APTES = 3-氨基丙基三乙氧基硅烷)生成MCM-41@APTES@HmC_3 (